Douglas Elliman Inc. (NYSE:DOUG – Get Free Report) rose 3% during mid-day trading on Tuesday . The stock traded as high as $1.37 and last traded at $1.36. Approximately 592,152 shares changed hands during trading, a decline of 32% from the average daily volume of 865,842 shares. The stock had previously closed at $1.32.
Douglas Elliman Stock Up 3.0 %
The firm’s 50-day moving average is $1.59 and its 200-day moving average is $1.97. The company has a market cap of $124.49 million, a PE ratio of -2.62 and a beta of 1.41.
Douglas Elliman (NYSE:DOUG – Get Free Report) last announced its quarterly earnings results on Friday, March 1st. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.05). Douglas Elliman had a negative net margin of 4.45% and a negative return on equity of 16.63%. The company had revenue of $214.14 million for the quarter, compared to analysts’ expectations of $254.52 million. During the same quarter in the prior year, the firm earned ($0.23) EPS. As a group, equities research analysts anticipate that Douglas Elliman Inc. will post 0.06 EPS for the current fiscal year.
Hedge Funds Weigh In On Douglas Elliman
About Douglas Elliman
Douglas Elliman Inc owns Douglas Elliman Realty, LLC, operating as a residential brokerage company in the United States with operations in New York, Florida, California, Texas, Colorado, Nevada, Massachusetts, Connecticut, Maryland, Virginia and Washington, DC In addition, Douglas Elliman sources, uses and invests in early-stage, disruptive property technology (“PropTech”) solutions and companies and provides other real estate services, including development marketing, property management and settlement and escrow services in select markets.
Featured Articles
- Five stocks we like better than Douglas Elliman
- 5 discounted opportunities for dividend growth investors
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- 3 REITs to Buy and Hold for the Long Term
- Hilton Demonstrates Asset Light is Right for Investors
- What is the Euro STOXX 50 Index?
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Douglas Elliman Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Douglas Elliman and related companies with MarketBeat.com's FREE daily email newsletter.